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The new European Society for Vascular Surgery (ESVS) guidelines on the management of abdominal 
aortic aneurysms (AAA) were produced by clinicians for clinicians, but for the first time in the history 
of ESVS guideline production the AAA guideline development process included input from the 
patients affected by the recommendations [1]. Even from the small patient contribution to these 
guidelines, and similar patient input to recent AAA repair trials, it is clear that the important 
outcomes for patients and their relatives may be very different from those usually considered 
important by vascular surgeons. In the IMPROVE trial it was observed that for patients, getting back 
home quickly, and without disability, may be more important than survival per se [2]. Time to going 
home is rarely reported in clinical trials of AAA repair. 
It is also evident from reading the new AAA guidelines that there are many recommendations based 
on weak evidence [1]. From a total of 125 recommendations in the AAA guidelines, only 7 could be 
supported by enough evidence to assign them as class I, level A. There remains uncertainty for many 
critical areas that may affect large numbers of patients or vascular services. For example, 
recommendations for the use of secondary cardiovascular prevention for patients with small AAA 
(Recommendation 21, class IIa, level B) and the treatment of type II endoleak (Recommendation 88, 
class IIa, level C) are based on limited/heterogeneous evidence. This is in part because evidence 
synthesis across different studies is hampered by inconsistent outcome reporting [3].   
For these two main reasons, the development of Core Outcome Sets (COS) for Vascular Surgery, 
applicable across Europe, is needed urgently. COS are collections of key outcomes which should be 
reported in all studies involving a certain patient group.  The means of measuring the selected 
outcomes also need to be carefully defined using validated tools (e.g. for quality of life) or agree 
definitions for outcomes such as time to going home.   COS need careful scoping before 
development, including the range of clinical circumstances covered (e.g. all AAA studies versus 
interventional studies only, elective and/or emergency procedures, with or without re-interventions) 
and the stakeholders who need to be involved.  They are developed using a two-phase process 
involving an identification phase and a rigorous consensus phase.  The identification phase usually 
involves a systematic review of what outcomes have been used previously, together with a variety of 
techniques including focus groups and expert panels.  The subsequent consensus phase usually 
employs a Delphi survey, where the level of consensus should be predefined. Key to both of these 
phases is the involvement of patients in addition to other stakeholders (clinicians, other healthcare 
professionals and sometimes industry or social care professionals). This is important at the 
identification phase, as there are an increasing number of examples of where patient identified 
outcomes which had never been the subject of prior research [4].  The development of a COS for 
trials in oesophageal resection surgery recently also highlighted the importance of including patients 
in the consensus phase, where some of the items eventually adopted as essential were voted as not 
essential by healthcare professionals during the first round of the consensus process [5].  COS have 
been developed for conditions as diverse as cancer resection, osteoarthritis and pain management 
[5-7].  Vascular surgeons have been slow to adopt this methodology: the authors were only able to 
identify two such projects in the COMET (Core Outcome Measures in Effectiveness Trials) database, 
an international registry of COS development projects [8].  Achieving an agreed international 
consensus provides an additional challenge but can be accomplished using expert panels and 
conference workshops. 
What benefits would COS for AAA repair and other vascular diseases bring? Primarily this would put 
patients at the centre of care through focusing the generation of evidence on outcomes that are 
important to patients, not those that are important to surgeons. The delivery of patient centred care 
is the foremost task for every doctor, including vascular surgeons. As we have seen in the ESVS AAA 
guideline development process and the IMPROVE trial, the needs of the patient are perceived quite 
differently by vascular surgeons and patients [1,2]. Therefore, there is an urgent need to address this 
disconnect. Returning to the example above from the IMPROVE Trial [2], comparing outcomes 
between endovascular and open repair for ruptured AAA, we can conclude that; had the trial 
restricted reporting to only traditional outcomes such as 30-day-mortality and number of major 
cardiovascular complications, outcomes of apparently vital interest to the patient with a ruptured 
AAA, such as returning home quickly without disability, would have been missed. Since patients 
presenting with AAA are often eligible for a wide range of complex procedures, knowing the 
priorities of patients in combination with knowledge on a diversity of meaningful outcomes for AAA 
repair would seem essential in successfully tailoring an AAA repair strategy for each individual 
patient. Establishing COS for AAA repair that reflect patient priorities will ensure that these 
outcomes are monitored and assessed in clinical practice, clinical registries and clinical audits as well 
as in AAA research, effectively putting the patient at the centre of care and aiding decision-making 
for health professionals. 
Concerning implementation of COS in AAA and other vascular research, the benefits of COS 
documented in other research areas should be expected [9].  Reduced heterogeneity, by ensuring 
that AAA trials that address similar clinical questions use the same outcomes, will ultimately 
facilitate evidence synthesis and meta-analyses. Reduction of selective outcome reporting will lead 
to reduced reporting bias. And lastly, increasing the relevance and impact of AAA trials, through 
involvement of all AAA stakeholders (patients, care givers and health professionals), will minimise 
the risk of trials delivering statistically significant findings but with little or no clinical relevance. 
Randomised trials are costly and often take many years to report, whilst technology advances 
rapidly.  Given this situation, guidelines will continue to need to synthesize evidence from registry 
data and observational studies.  The use of COS based reporting in such studies would facilitate 
evidence synthesis and produce better quality evidence for the future. 
We suggest that the development of COS should be conducted in parallel with all future ESVS 
guidelines and hope that such an initiative would be considered sympathetically. For now, we intend 
to initiate this process with AAA repair and wish to widen the initiative to more countries than the 
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